By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Neurovascular access is used to treat a variety of illnesses and problems, including embolic stroke, brain aneurysms, arteriovenous malformations, and other issues.
Any device used to distribute a product in the field is referred to as a delivery device (excluding syringes or other similar devices that are generally available for purchase).
The global neurovascular access and delivery device market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
CERENOVUS, a new neurovascular company, was recently unveiled by Johnson & Johnson Medical Devices Companies during the Society of NeuroInterventional Surgery. The mission of CERENOVUS, whose name is a combination of the Latin words for “new” and “brain,” is to provide patients with hemorrhagic and ischemic strokes with cutting-edge therapies.
The Johnson & Johnson Medical Devices Companies are dedicated to providing neurovascular care and have recently made targeted investments to increase the product portfolio for CERENOVUS.
The recent acquisitions of Neuravi Limited, with its EmboTrap Revascularization Platform, and Pulsar Vascular Inc., with a focus on the endovascular treatment of wide-neck bifurcation aneurysms, significantly increase CERENOVUS’s capacity to meet unmet clinical requirements in these fields.
Haselmeier, a manufacturer and developer of Swiss-German medication delivery devices, has been acquired by Sulzer.For the secure self-administration of liquid medications, Haselmeier is involved in the supply of solutions for subcutaneous injection systems.
The business sells subcutaneous self-injection pens and other drug delivery systems using its own intellectual property for conditions like diabetes, osteoporosis, and growth abnormalities.
Haselmeier offers solutions tailored to the needs of each client, from design and conception to product development, engineering, and industrialization in cutting-edge manufacturing facilities.
In order to lessen the difficulties encountered on a daily basis when working in this environment, the CorPath GRX Neurovascular System provides procedural precision, greater visualisation, and an optimum work environment during cerebral aneurysm treatments.
The goal of Siemens Healthineers’ image-guided, robotic-assisted therapy is to improve patient outcomes while speeding the development of neurovascular technology today.
The recently acquired radial artery access portfolio from Rist Neurovascular, Inc., which comprises the Rist 079 radial access guide catheter and Rist radial access selective catheter, has been expanded by Medtronic for its limited site release.
The first catheter created exclusively for neurointerventions using the radial artery channel in the wrist is the Rist 079 Radial Access Guide Catheter. When compared to the femoral method, this is the first-of-its-kind device that optimises transition zones for the necessary navigability and support.
Today, industry and the medical community work together more and more to achieve medical breakthroughs. Physicians more frequently present an idea to the industry and, as a result of that collaboration, obtain funding for additional capabilities in research and development in order to provide a treatment solution that is more likely to become a standard treatment.
The medical device industry’s workforce is here for the same reasons that medical professionals are; They want to assist others. We want to provide a treatment that has an impact. In order to assist the industry in providing therapies that are known to be effective, efficient, and effective, regulatory bodies frequently make requests for information and documentation on therapies.
A crucial requirement is for a physician to receive training on interventions. Training is more than just learning about the nuances of a new device that has been approved for sale. You are obligated to provide instruction on everything from additional considerations of pre-, peri-, and post-procedure to device setup, initial access, and delivery education and training.
Viz.ai and Cercare Medical Partner to Support Neurovascular Clinical Decision Making. Cercare Medical, which provides next-level medical imaging with CT and MRI, and Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced a partnership today. Cercare Perfusion, a patient-specific, fully automated perfusion software, will be incorporated into the Viz.ai platform as part of the partnership.
In order to better serve healthcare facilities that use MR imaging in the patient workflow, Viz is expanding its imaging capabilities and features. The capabilities of the Viz.ai platform and the company’s flagship AI-powered neurovascular portfolio are enhanced by the incorporation of Cercare Perfusion technology.
Cercare further enriches the workflow with layers of AI to produce volumetric measures, which directly impact clinical decision-making. Brain perfusion scans measure blood flow in the brain and are used to provide critically needed information on the extent of tissue damage caused, for example, by acute ischemic stroke.
Quickly mapping brain perfusion deficits is crucial for minimizing tissue damage in acute stroke management.Viz.ai entered into this global partnership to increase access to the latest perfusion technology, which is designed to easily integrate into existing workflows to provide healthcare professionals with deep, fast, and reliable patient insights.
Cercare uniquely provides maps illustrating oxygen availability, in addition to blood flow and volume. This allows more detailed assessment of tissue pathology and therefore optimized patient management for a variety of conditions, such as dementia and neoplasia.
